24 May

Plausibility after pregabalin – how much information must a patent disclose?

Plausibility has been increasingly important in life sciences patent prosecution and litigation in recent years, including in the UK Supreme Court. Due to the growing significance of second medical use claims in biopharma innovation, rights holders should ensure that they properly understand this complex area

Matthew Royle


Taylor & Wessing

Paul England

Senior associate and senior professional support lawyer

Taylor & Wessing